vs

Side-by-side financial comparison of DORCHESTER MINERALS, L.P. (DMLP) and PUMA BIOTECHNOLOGY, INC. (PBYI). Click either name above to swap in a different company.

PUMA BIOTECHNOLOGY, INC. is the larger business by last-quarter revenue ($75.5M vs $41.9M, roughly 1.8× DORCHESTER MINERALS, L.P.). On growth, PUMA BIOTECHNOLOGY, INC. posted the faster year-over-year revenue change (27.7% vs 5.4%). Over the past eight quarters, PUMA BIOTECHNOLOGY, INC.'s revenue compounded faster (31.3% CAGR vs 16.2%).

Dorchester Minerals, L.P. is a publicly traded master limited partnership based in the United States. It acquires, owns, and manages a diversified portfolio of royalty interests, net profit interests, and mineral properties associated with oil, natural gas, and natural gas liquids production across key onshore U.S. energy basins, delivering stable cash flow returns to its unitholders.

Puma Biotechnology is a publicly traded biopharmaceutical company headquartered in Los Angeles, CA.

DMLP vs PBYI — Head-to-Head

Bigger by revenue
PBYI
PBYI
1.8× larger
PBYI
$75.5M
$41.9M
DMLP
Growing faster (revenue YoY)
PBYI
PBYI
+22.3% gap
PBYI
27.7%
5.4%
DMLP
Faster 2-yr revenue CAGR
PBYI
PBYI
Annualised
PBYI
31.3%
16.2%
DMLP

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
DMLP
DMLP
PBYI
PBYI
Revenue
$41.9M
$75.5M
Net Profit
$16.2M
Gross Margin
69.3%
Operating Margin
22.7%
Net Margin
38.7%
Revenue YoY
5.4%
27.7%
Net Profit YoY
13.7%
EPS (diluted)
$0.26

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
DMLP
DMLP
PBYI
PBYI
Q4 25
$41.9M
$75.5M
Q3 25
$35.4M
$54.5M
Q2 25
$32.4M
$52.4M
Q1 25
$43.2M
$46.0M
Q4 24
$39.7M
$59.1M
Q3 24
$53.5M
$80.5M
Q2 24
$37.4M
$47.1M
Q1 24
$31.0M
$43.8M
Net Profit
DMLP
DMLP
PBYI
PBYI
Q4 25
$16.2M
Q3 25
$11.2M
$8.8M
Q2 25
$12.3M
$5.9M
Q1 25
$17.6M
$3.0M
Q4 24
$14.2M
Q3 24
$36.4M
$20.3M
Q2 24
$23.6M
$-4.5M
Q1 24
$18.2M
$-4.8M
Gross Margin
DMLP
DMLP
PBYI
PBYI
Q4 25
69.3%
Q3 25
77.7%
Q2 25
76.5%
Q1 25
77.1%
Q4 24
76.4%
Q3 24
63.9%
Q2 24
77.4%
Q1 24
75.5%
Operating Margin
DMLP
DMLP
PBYI
PBYI
Q4 25
22.7%
Q3 25
17.6%
Q2 25
12.7%
Q1 25
8.7%
Q4 24
22.6%
Q3 24
27.4%
Q2 24
-4.6%
Q1 24
-5.3%
Net Margin
DMLP
DMLP
PBYI
PBYI
Q4 25
38.7%
Q3 25
31.5%
16.2%
Q2 25
38.1%
11.2%
Q1 25
40.9%
6.5%
Q4 24
35.9%
Q3 24
68.1%
25.2%
Q2 24
63.2%
-9.6%
Q1 24
58.6%
-11.0%
EPS (diluted)
DMLP
DMLP
PBYI
PBYI
Q4 25
$0.26
Q3 25
$0.17
Q2 25
$0.12
Q1 25
$0.06
Q4 24
$0.40
Q3 24
$0.41
Q2 24
$-0.09
Q1 24
$-0.10

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
DMLP
DMLP
PBYI
PBYI
Cash + ST InvestmentsLiquidity on hand
$41.9M
$97.5M
Total DebtLower is stronger
$22.7M
Stockholders' EquityBook value
$130.3M
Total Assets
$309.6M
$216.3M
Debt / EquityLower = less leverage
0.17×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
DMLP
DMLP
PBYI
PBYI
Q4 25
$41.9M
$97.5M
Q3 25
$41.6M
$94.4M
Q2 25
$36.5M
$96.0M
Q1 25
$41.5M
$93.2M
Q4 24
$42.5M
$101.0M
Q3 24
$56.5M
$96.7M
Q2 24
$35.2M
$96.8M
Q1 24
$37.7M
$107.2M
Total Debt
DMLP
DMLP
PBYI
PBYI
Q4 25
$22.7M
Q3 25
$34.0M
Q2 25
$45.3M
Q1 25
$56.7M
Q4 24
$68.0M
Q3 24
$79.3M
Q2 24
$90.7M
Q1 24
$102.0M
Stockholders' Equity
DMLP
DMLP
PBYI
PBYI
Q4 25
$130.3M
Q3 25
$115.3M
Q2 25
$104.7M
Q1 25
$97.1M
Q4 24
$92.1M
Q3 24
$71.1M
Q2 24
$48.5M
Q1 24
$51.0M
Total Assets
DMLP
DMLP
PBYI
PBYI
Q4 25
$309.6M
$216.3M
Q3 25
$330.4M
$202.9M
Q2 25
$325.6M
$194.9M
Q1 25
$349.0M
$196.2M
Q4 24
$366.8M
$213.3M
Q3 24
$403.4M
$220.7M
Q2 24
$176.0M
$205.0M
Q1 24
$184.8M
$214.1M
Debt / Equity
DMLP
DMLP
PBYI
PBYI
Q4 25
0.17×
Q3 25
0.30×
Q2 25
0.43×
Q1 25
0.58×
Q4 24
0.74×
Q3 24
1.12×
Q2 24
1.87×
Q1 24
2.00×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
DMLP
DMLP
PBYI
PBYI
Operating Cash FlowLast quarter
$34.3M
$14.4M
Free Cash FlowOCF − Capex
$14.4M
FCF MarginFCF / Revenue
19.1%
Capex IntensityCapex / Revenue
0.0%
Cash ConversionOCF / Net Profit
2.12×
TTM Free Cash FlowTrailing 4 quarters
$41.7M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
DMLP
DMLP
PBYI
PBYI
Q4 25
$34.3M
$14.4M
Q3 25
$34.3M
$9.7M
Q2 25
$30.5M
$14.1M
Q1 25
$33.4M
$3.6M
Q4 24
$31.5M
$15.6M
Q3 24
$43.7M
$11.0M
Q2 24
$29.4M
$1.0M
Q1 24
$28.0M
$11.2M
Free Cash Flow
DMLP
DMLP
PBYI
PBYI
Q4 25
$14.4M
Q3 25
$9.7M
Q2 25
$14.1M
Q1 25
$3.6M
Q4 24
$15.6M
Q3 24
$11.0M
Q2 24
$1.0M
Q1 24
FCF Margin
DMLP
DMLP
PBYI
PBYI
Q4 25
19.1%
Q3 25
17.7%
Q2 25
26.8%
Q1 25
7.7%
Q4 24
26.4%
Q3 24
13.7%
Q2 24
2.1%
Q1 24
Capex Intensity
DMLP
DMLP
PBYI
PBYI
Q4 25
0.0%
Q3 25
0.0%
Q2 25
0.0%
Q1 25
0.1%
Q4 24
0.0%
Q3 24
0.0%
Q2 24
0.0%
Q1 24
0.0%
Cash Conversion
DMLP
DMLP
PBYI
PBYI
Q4 25
2.12×
Q3 25
3.07×
1.10×
Q2 25
2.47×
2.41×
Q1 25
1.89×
1.21×
Q4 24
2.21×
Q3 24
1.20×
0.54×
Q2 24
1.25×
Q1 24
1.54×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

DMLP
DMLP

Royalties$34.0M81%
Other$7.8M19%

PBYI
PBYI

Segment breakdown not available.

Related Comparisons